Drug-resistant tuberculosis （TB） poses a significant challenge to the successful treatment and control of TB worldwide. Resistance to anti-TB drugs has existed since the beginning of the chemotherapy era. New insigh...Drug-resistant tuberculosis （TB） poses a significant challenge to the successful treatment and control of TB worldwide. Resistance to anti-TB drugs has existed since the beginning of the chemotherapy era. New insights into the resistant mechanisms of anti-TB drugs have been provided. Better understanding of drug resistance mechanisms helps in the development of new tools for the rapid diagnosis of drug- resistant TB. There is also a pressing need in the development of new drugs with novel targets to improve the current treatment of TB and to prevent the emergence of drug resistance in Mycobacterium tuber- culosis. This review summarizes the anti-TB drug resistance mechanisms, furnishes some possible novel drug targets in the development of new agents for TB therapy and discusses the usefulness using known targets to develop new anti-TB drugs. Whole genome sequencing is currently an advanced technology to uncover drug resistance mechanisms in M. tuberculosis. However, further research is required to unravel the significance of some newly discovered gene mutations in their contribution to drug resistance.展开更多
The first antibody-drug conjugate(ADC),Mylotarg,received FDA approval in 2000,and the revolutionary targeted cancer chemotherapy drug,Imatinib(Gleevec),was approved by FDA in 2001.Accordingly,it is an excellent time t...The first antibody-drug conjugate(ADC),Mylotarg,received FDA approval in 2000,and the revolutionary targeted cancer chemotherapy drug,Imatinib(Gleevec),was approved by FDA in 2001.Accordingly,it is an excellent time to review the recent advances in tumor-targeting chemotherapy drugs by collecting articles from leading researchers at the 20th anniversary of the FDA approvals of these two epoch-making anticancer drugs with two different approaches to targeting cancer cells specifically.In this Special Issue,recent advances in these two approaches are presented.展开更多
The first antibody-drug conjugate(ADC),Mylotarg,received FDA approval in 2000,and the revolutionary targeted cancer chemotherapy drug,Imatinib(Gleevec),was approved by FDA in 2001.Accordingly,it is an excellent time t...The first antibody-drug conjugate(ADC),Mylotarg,received FDA approval in 2000,and the revolutionary targeted cancer chemotherapy drug,Imatinib(Gleevec),was approved by FDA in 2001.Accordingly,it is an excellent time to review the recent advances in tumor-targeting chemotherapy drugs by collecting articles from leading researchers at the 20th anniversary of the FDA approvals of these two epoch-making anticancer drugs with two different approaches to targeting cancer cells specifically.In this Special Issue,recent advances in these two approaches are presented.展开更多
基金supported by the National Natural Science Foundation of China(No.81572037)the One Hundred Talents Program of the Chinese Academy of Sciences(Category A,to T.Z.)+8 种基金the Open Project Grant(No.2014SKLRD-006)the Key Project Grant(No.SKLRD2016ZJ003)the State Key Laboratory of Respiratory Diseases,Guangzhou Institute of Respiratory Disease,First Allied Hospital of Guangzhou Medical Universitythe PhD Start-up Fund of Natural Science Foundation,Guangdong Province, China(No.2016A030310123 to J.G.)the Chinese Academy of Sciences-Commonwealth Scientific and Industrial Research Organization Mutual Grant(No.154144KYSB20150045)partially financed by Guangzhou Municipal Industry and Research Collaborative Innovation Program(Nos.201508020248 and 201604020019)Guangzhou Municipal Clinical Medical Center Program(No.155700012)sponsored by CASTWAS President's PhD Fellowship Program(to M.M.I,and C.C.)UCAS Fellowship Program(to H.M.A.H.and J.M.) for international PhD students
文摘Drug-resistant tuberculosis （TB） poses a significant challenge to the successful treatment and control of TB worldwide. Resistance to anti-TB drugs has existed since the beginning of the chemotherapy era. New insights into the resistant mechanisms of anti-TB drugs have been provided. Better understanding of drug resistance mechanisms helps in the development of new tools for the rapid diagnosis of drug- resistant TB. There is also a pressing need in the development of new drugs with novel targets to improve the current treatment of TB and to prevent the emergence of drug resistance in Mycobacterium tuber- culosis. This review summarizes the anti-TB drug resistance mechanisms, furnishes some possible novel drug targets in the development of new agents for TB therapy and discusses the usefulness using known targets to develop new anti-TB drugs. Whole genome sequencing is currently an advanced technology to uncover drug resistance mechanisms in M. tuberculosis. However, further research is required to unravel the significance of some newly discovered gene mutations in their contribution to drug resistance.
文摘The first antibody-drug conjugate(ADC),Mylotarg,received FDA approval in 2000,and the revolutionary targeted cancer chemotherapy drug,Imatinib(Gleevec),was approved by FDA in 2001.Accordingly,it is an excellent time to review the recent advances in tumor-targeting chemotherapy drugs by collecting articles from leading researchers at the 20th anniversary of the FDA approvals of these two epoch-making anticancer drugs with two different approaches to targeting cancer cells specifically.In this Special Issue,recent advances in these two approaches are presented.
文摘The first antibody-drug conjugate(ADC),Mylotarg,received FDA approval in 2000,and the revolutionary targeted cancer chemotherapy drug,Imatinib(Gleevec),was approved by FDA in 2001.Accordingly,it is an excellent time to review the recent advances in tumor-targeting chemotherapy drugs by collecting articles from leading researchers at the 20th anniversary of the FDA approvals of these two epoch-making anticancer drugs with two different approaches to targeting cancer cells specifically.In this Special Issue,recent advances in these two approaches are presented.
